washington  reuters    a u s  congressional committee has launched an examination of the food and drug administration s criminal office  raising questions about the unit s management and handling of cases involving food  drugs and devices  the house energy and commerce committee told fda commissioner robert califf it is  examining management concerns  and  possible morale concerns with the field offices  of the office of criminal investigations  the september  letter  signed by committee chairman fred upton and tim murphy  chairman of the subcommittee on oversight and investigations  seeks answers to a detailed list of questions by october   among other issues  the house committee questions why george karavetsos  director of the rockville  maryland based fda criminal office  is allowed to run the unit from an office in south florida  near his home  an fda spokeswoman said the agency received the letter and will respond to the committee directly  the house questions come two weeks after reuters reported how some fda agents complain criminal office managers have forced them to pursue cases involving mislabeled foreign imported injectable drugs  at the expense of cases with more potential to protect the public health  current and former agents complain they have turned into the  botox police   spending thousands of hours chasing doctors who purchased authentic versions of allergan s anti wrinkle drug that were labeled for use in other countries  some agents say their efforts have done little more than protect the pharmaceutical industry s high drug prices in the united states  those concerns come as the criminal office has had mixed success in bringing cases  from fiscal year    reuters found  more than half of all opened oci cases were closed without action  the house committee asked califf to explain the process for how criminal cases get opened  and to provide statistics on oci s arrests  convictions  case initiations and amount of money recovered  reuters also reported on karavetsos  relocation to florida  a move that came less than two years after the fda paid more than    to move him to maryland  karavetsos  in a prior interview  defended the office s efforts  saying statistics are not a fair measure of oci s success because public health and safety will  always trump the criminal investigation    fda regulatory affairs associate commissioner melinda plaisier defended karavetsos  move to miami  saying it was good for the fda and his family  the house committee letter also questions how the fda responded to two prior reports  from the government accountability office and the health and human services office of the inspector general  that were critical of the criminal office  the  oig report cited problems with how the rockville based office is run and concluded that field offices  lack the discretion  to open cases to address  food and drug concerns prevalent in their locales   the report cited a lack of independence within the fda s criminal office  oci is housed within the office of regulatory affairs  which is responsible for compliance inspections and helps determine the criminal office s budget  the inspector general recommended structural changes to  ensure the independence of investigations   fda leadership at that time rejected those suggestions  the criminal office headquarters controls the opening of investigations  some agents have questioned the office s priorities and say they have  on occasion  been told not to open cases involving other federal agencies  a september  email from robert west  the recently retired special agent in charge of the miami field office  is one example  west  in the email  contended agencies including the fbi  the hhs oig and homeland security investigators  were riding our coattails and were not bringing anything to the table   involving those agencies in an investigation from day one  he wrote   is unacceptable   west previously declined interview requests  reuters could not immediately reach him tuesday through an fda spokeswoman  